Compile Data Set for Download or QSAR
Report error Found 65 Enz. Inhib. hit(s) with all data for entry = 1075
TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM307542(US10150747, Example 9 | 5-(3-((2-(1,2,4-Oxadiazol-...)
Affinity DataIC50: 0.603nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM307547(US10150747, Example 14 | BDBM307549 | N-(2-(1,2,4-...)
Affinity DataIC50: 1.52nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM307550(US10150747, Example 17 | N-(2-cyanopropan-2-yl)-5-...)
Affinity DataIC50: 1.84nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM307545(US10150747, Example 12 | 6-Ethoxy-2-(4-fluoropheny...)
Affinity DataIC50: 1.89nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM307542(US10150747, Example 9 | 5-(3-((2-(1,2,4-Oxadiazol-...)
Affinity DataEC50:  1.97nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM307561(US10150747, Example 28 | 5-(3-((2-cyanopropan-2-yl...)
Affinity DataEC50:  2.01nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM307561(US10150747, Example 28 | 5-(3-((2-cyanopropan-2-yl...)
Affinity DataIC50: 2.04nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM307566(US10150747, Example 33 | 5-(3-((2-(1,2,4-thiadiazo...)
Affinity DataIC50: 2.04nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM307542(US10150747, Example 9 | 5-(3-((2-(1,2,4-Oxadiazol-...)
Affinity DataIC50: 2.22nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM307542(US10150747, Example 9 | 5-(3-((2-(1,2,4-Oxadiazol-...)
Affinity DataEC50:  2.38nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM307558(US10150747, Example 25 | 5-(3-((2-(1,2,4-oxadiazol...)
Affinity DataIC50: 2.48nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM307548(US10150747, Example 15 | N-(bicyclo[1.1.1]pentan-1...)
Affinity DataIC50: 2.48nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM307566(US10150747, Example 33 | 5-(3-((2-(1,2,4-thiadiazo...)
Affinity DataEC50:  2.49nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM307546(US10150747, Example 13 | 5-(6-Ethoxy-2-(4-fluoroph...)
Affinity DataIC50: 2.72nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM307547(US10150747, Example 14 | BDBM307549 | N-(2-(1,2,4-...)
Affinity DataIC50: 2.73nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM307550(US10150747, Example 17 | N-(2-cyanopropan-2-yl)-5-...)
Affinity DataEC50:  2.80nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM307551(US10150747, Example 18 | 5-(3-((2-(1,2,4-oxadiazol...)
Affinity DataIC50: 2.83nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM307551(US10150747, Example 18 | 5-(3-((2-(1,2,4-oxadiazol...)
Affinity DataEC50:  2.85nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM307547(US10150747, Example 14 | BDBM307549 | N-(2-(1,2,4-...)
Affinity DataEC50:  2.95nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM307562(US10150747, Example 29 | 5-(2-(4-Fluorophenyl)-3-(...)
Affinity DataIC50: 2.95nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM307543(US10150747, Example 10 | 5-(3-((2-Cyanopropan-2-yl...)
Affinity DataIC50: 3.02nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM307547(US10150747, Example 14 | BDBM307549 | N-(2-(1,2,4-...)
Affinity DataEC50:  3.20nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM307564(US10150747, Example 31 | N-(2-(1,2,4-Oxadiazol-3-y...)
Affinity DataEC50:  3.21nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM307539(5-(3-((2-(1,2,4-Oxadiazol-3-yl)propan-2-yl)carbamo...)
Affinity DataIC50: 3.31nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM307546(US10150747, Example 13 | 5-(6-Ethoxy-2-(4-fluoroph...)
Affinity DataEC50:  3.67nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM307537(US10150747, Example 4 | 5-(3-(Bicyclo[1.1.1]pentan...)
Affinity DataIC50: 3.88nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM307567(US10150747, Example 34 | 5-(3-((2-(1,2,4-Oxadiazol...)
Affinity DataIC50: 3.89nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM307535(US10150747, Example 2 | 2-(4-Fluorophenyl)-5-(4-me...)
Affinity DataIC50: 4.15nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM307552(US10150747, Example 19 | 5-(3-((2-(1,2,4-Oxadiazol...)
Affinity DataIC50: 4.20nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM307545(US10150747, Example 12 | 6-Ethoxy-2-(4-fluoropheny...)
Affinity DataEC50:  4.20nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM307538(US10150747, Example 5 | 5-(3-(Bicyclo[1.1.1]pentan...)
Affinity DataIC50: 4.30nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM307536(US10150747, Example 3 | 5-(4-Fluoro-3-((1-(pyrimid...)
Affinity DataIC50: 4.38nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM307554(US10150747, Example 21 | 5-(3-((2-(1,2,4-oxadiazol...)
Affinity DataIC50: 4.49nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM307553(US10150747, Example 20 | 6-(2,2-difluoroethoxy)-2-...)
Affinity DataIC50: 4.54nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM307562(US10150747, Example 29 | 5-(2-(4-Fluorophenyl)-3-(...)
Affinity DataEC50:  4.57nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM307541(US10150747, Example 8 | 5-(3-((1-Cyanocyclopropyl)...)
Affinity DataIC50: 4.97nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM307543(US10150747, Example 10 | 5-(3-((2-Cyanopropan-2-yl...)
Affinity DataEC50:  5.01nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM307539(5-(3-((2-(1,2,4-Oxadiazol-3-yl)propan-2-yl)carbamo...)
Affinity DataIC50: 5.05nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM307540(US10150747, Example 7 | 6-Ethoxy-2-(4-fluorophenyl...)
Affinity DataIC50: 5.78nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM307565(US10150747, Example 32 | 5-(3-((2-(3H-imidazo[4,5-...)
Affinity DataIC50: 6.01nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM307558(US10150747, Example 25 | 5-(3-((2-(1,2,4-oxadiazol...)
Affinity DataEC50:  6.23nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM307535(US10150747, Example 2 | 2-(4-Fluorophenyl)-5-(4-me...)
Affinity DataEC50:  6.24nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM307538(US10150747, Example 5 | 5-(3-(Bicyclo[1.1.1]pentan...)
Affinity DataEC50:  6.5nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM307536(US10150747, Example 3 | 5-(4-Fluoro-3-((1-(pyrimid...)
Affinity DataEC50:  6.70nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM307553(US10150747, Example 20 | 6-(2,2-difluoroethoxy)-2-...)
Affinity DataEC50:  6.79nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM307539(5-(3-((2-(1,2,4-Oxadiazol-3-yl)propan-2-yl)carbamo...)
Affinity DataEC50:  6.88nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM307548(US10150747, Example 15 | N-(bicyclo[1.1.1]pentan-1...)
Affinity DataEC50:  7.03nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM307556(US10150747, Example 23 | 5-(3-((2-(1,2,4-Oxadiazol...)
Affinity DataIC50: 7.14nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM307552(US10150747, Example 19 | 5-(3-((2-(1,2,4-Oxadiazol...)
Affinity DataEC50:  7.41nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetGenome polyprotein(HCV)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM307534(US10150747, Example 1 | 2-(4-Fluorophenyl)-N-methy...)
Affinity DataIC50: 7.42nMAssay Description:To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

Displayed 1 to 50 (of 65 total ) | Next | Last >>
Jump to: